By Eden Joy Pacsial-Ong, Ph.D., Nerac Analyst
Originally Published: September 26, 2017
The Biologics Price Competition and Innovations Act (BPCIA) was enacted to address the regulatory aspects, approval pathway and market entry of biosimilar drugs. This article looks at the case of Sandoz Inc. v. Amgen Inc., regarding its interpretation of the (BPCIA) and the potential effects of the process initiated by the BPCIA provisions. Read more here.